Navigation Links
Shanghai ChemPartner and ELARA Pharmaceuticals Expand Drug Discovery Collaboration to a New Level
Date:8/4/2009

SHANGHAI, Aug. 4 /PRNewswire-Asia/ -- Shanghai ChemPartner Co., Ltd., (ChemPartner) a wholly owned subsidiary of ShangPharma Corporation, announced today that it has moved its drug discovery collaboration with ELARA Pharmaceuticals to a new level. ChemPartner will provide fully integrated services in the areas of DMPK, pharmacology and toxicology for ELARA's lead oncology programs. Members of the joint project team from both sides will work closely together to design and execute a drug screening cascade.

"This new relationship is a natural result of the high quality services provided by ChemPartner," commented Dr. Joe Lewis, CEO and a founder of ELARA Pharmaceuticals. "The discovery support from ChemPartner helped our Hypoxia Signaling inhibitor program to move from academic discovery stage to early proof of concept. This led to a successful spin off from the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany. Our new integrated relationship will enable ELARA to further leverage ChemPartner's strong R&D capabilities from discovery to early development phase. We anticipate a stronger strategic partnership down the road as our program progresses."

"We are very pleased to see that our services helped ELARA turn innovative research at a renowned academic institution into a venture funded drug discovery company," said Michael Hui, founder and CEO of ChemPartner. "Our partnership demonstrates the strength of ChemPartner's innovation driven and fully integrated R&D service platform"

About Shanghai ChemPartner

Founded in 2003, Shanghai ChemPartner Company Ltd. (ChemPartner) is one of the leading contract research organizations providing medicinal chemistry, discovery biology, pharmacology, DMPK, toxicology, process R&D, analytical development, formulation and contract manufacturing services to over 80 pharmaceutical and biotech companies in the world. ChemPartner currently has a team of over 1000 scientists including over 80 senior scientific leaders with extensive industry experiences gained from leading global pharmaceutical and biotech companies.

Further information is available at http://www.shangpharma.com .

About ELARA Pharmaceuticals

ELARA Pharmaceuticals is a spin-off of the European Molecular Biology Laboratory in Heidelberg, and was founded to translate basic research findings into novel cancer treatments.

The company is developing a portfolio of highly-potent orally-available inhibitors of the hypoxia signalling pathway. The lead compound shows an excellent in vivo profile and is expected to move into formal preclinical development this year.

Further information is available at http://www.elarapharma.com .


'/>"/>
SOURCE Shanghai ChemPartner Co., Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Shanghai Century Acquisition Corporation Announces Sichuan Kelun Pharmaceutical Co Results for the Six Months Ended June 30, 2007
2. HUYA Bioscience International Licenses Clinical Stage Anti-Arrhythmic Compound from the Shanghai Institute of Materia Medica
3. Cinpathogen Brings Together Over 40 Shanghai Area Hospitals at the First Annual Cinpathogen Hematology Conference
4. Cinpathogen Provides Clinical Diagnostic Consulting Services to Shanghai Area Hospitals
5. Shanghai CRO Service Alliance Adds Clinical Development Capabilities
6. Carna Biosciences Signs Distribution Agreement with Shanghai Universal Biotech Company
7. Cynvec to Present at the 11th Annual Shanghai International Forum on Biotechnology and Pharmaceutical Industry
8. NeoStem Signs Agreement with Shanghai Corporation to Develop A Stem Cell Collection and Treatment Network in Shanghai, Taiwan and Other Targeted China Provinces
9. Sundia and 2 Other CRO Companies Granted Express Customs Clearance Privilege in Shanghai
10. Shanghai ChemPartner and Agios Expand Integrated Drug Discovery Research Collaboration
11. Sundia Shortens CRO Shipment Delivery Time with Express Customs Clearance in Shanghai
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... March 24, 2017 Agenus Inc. (NASDAQ: AGEN), ... antibodies and cancer vaccines, today announced participation at the ...  Annual William Blair and Maidstone Life Sciences conference "Cancer ... in New York, NY . Agenus ... 29 at 9:40 am: Robert B. Stein , ...
(Date:3/23/2017)... 23, 2017 Research and Markets has ... report to their offering. ... The Global Market for Bioproducts ... 2016 at a CAGR of 8.9%, This ... bioproducts into seven major product segments: bio-derived chemicals, biofuels, pharmaceuticals ...
(Date:3/23/2017)... Colo. , March 23, 2017  GlobeImmune, Inc. ... agreement for the sale of 12,835,490 shares of its ... NantWorks  ecosystem of companies. In connection with the sale of ... $100,000 in cash and issue to GlobeImmune 200,000 shares, ... stock. "We are pleased to enter ...
(Date:3/23/2017)... 2017 Kineta, Inc., a biotechnology company ... in immuno-oncology, today announced the discovery and characterization ... that activate interferon response factor 3 (IRF3) via ... tumor regression in a murine colon carcinoma mouse ... complete tumor regression to initial drug treatment were ...
Breaking Biology Technology:
(Date:3/20/2017)... PMD Healthcare announces the release of its ... System (WMS), a remote, real-time lung health monitoring and ... is a Medical Device, Digital Health, and Chronic Care ... innovative solutions that empower people to improve their healthcare ... developed the first ever personal spirometer, Spiro PD, which ...
(Date:3/9/2017)... FRANCISCO and MOUNTAIN VIEW, Calif. ... , "Eating Well Made Simple," and 23andMe , ... help guide better food choices.  Zipongo can now provide ... their food preferences, health goals and biometrics, but also ... certain food choices. Zipongo,s personalized food decision ...
(Date:3/2/2017)... NEW YORK , March 2, 2017 Summary ... to better understand Perrigo and its partnering interests and activities ... ... The Partnering Deals and Alliance since 2010 report provides an ... world,s leading life sciences companies. On demand company ...
Breaking Biology News(10 mins):